Microbiome Therapeutics for Clostridioides difficile Infection

Christine W. Lucky; Rachel L. Medernach; Brendan J. Kelly; Jennie H. Kwon; Michael H. Woodworth

doi:10.1016/j.idc.2025.07.007

Microbiome Therapeutics for Clostridioides difficile Infection

Christine W. Lucky
, Rachel L. Medernach
, Brendan J. Kelly
, Jennie H. Kwon
, Michael H. Woodworth

Research output: Contribution to journal › Article › peer-review

2 Scopus citations

Abstract

Microbiota-based therapies are used increasingly for the treatment and prevention of Clostridioides difficile infection (CDI), particularly in cases of recurrent CDI (rCDI). This review discusses the different types of microbiota-based therapies, including fecal microbiota transplant, fecal microbiota products, and live biotherapeutic products. The authors present efficacy data regarding clinical use in rCDI and highlight the unique aspects of each product.

Original language	English
Pages (from-to)	663-683
Number of pages	21
Journal	Infectious disease clinics of North America
Volume	39
Issue number	4
DOIs	https://doi.org/10.1016/j.idc.2025.07.007
State	Published - Dec 2025

Keywords

Clostridioides difficile infection
Fecal microbiota products
Fecal microbiota transplant
Live biotherapeutic products
Microbiome
Recurrent C difficile

Access to Document

10.1016/j.idc.2025.07.007

Cite this

@article{6d9ab415aee04814afe41061a10033f0,

title = "Microbiome Therapeutics for Clostridioides difficile Infection",

abstract = "Microbiota-based therapies are used increasingly for the treatment and prevention of Clostridioides difficile infection (CDI), particularly in cases of recurrent CDI (rCDI). This review discusses the different types of microbiota-based therapies, including fecal microbiota transplant, fecal microbiota products, and live biotherapeutic products. The authors present efficacy data regarding clinical use in rCDI and highlight the unique aspects of each product.",

keywords = "Clostridioides difficile infection, Fecal microbiota products, Fecal microbiota transplant, Live biotherapeutic products, Microbiome, Recurrent C difficile",

author = "Lucky, \{Christine W.\} and Medernach, \{Rachel L.\} and Kelly, \{Brendan J.\} and Kwon, \{Jennie H.\} and Woodworth, \{Michael H.\}",

note = "Publisher Copyright: {\textcopyright} 2025 Elsevier Inc.",

year = "2025",

month = dec,

doi = "10.1016/j.idc.2025.07.007",

language = "English",

volume = "39",

pages = "663--683",

journal = "Infectious disease clinics of North America",

issn = "0891-5520",

number = "4",

}

TY - JOUR

T1 - Microbiome Therapeutics for Clostridioides difficile Infection

AU - Lucky, Christine W.

AU - Medernach, Rachel L.

AU - Kelly, Brendan J.

AU - Kwon, Jennie H.

AU - Woodworth, Michael H.

PY - 2025/12

Y1 - 2025/12

N2 - Microbiota-based therapies are used increasingly for the treatment and prevention of Clostridioides difficile infection (CDI), particularly in cases of recurrent CDI (rCDI). This review discusses the different types of microbiota-based therapies, including fecal microbiota transplant, fecal microbiota products, and live biotherapeutic products. The authors present efficacy data regarding clinical use in rCDI and highlight the unique aspects of each product.

AB - Microbiota-based therapies are used increasingly for the treatment and prevention of Clostridioides difficile infection (CDI), particularly in cases of recurrent CDI (rCDI). This review discusses the different types of microbiota-based therapies, including fecal microbiota transplant, fecal microbiota products, and live biotherapeutic products. The authors present efficacy data regarding clinical use in rCDI and highlight the unique aspects of each product.

KW - Clostridioides difficile infection

KW - Fecal microbiota products

KW - Fecal microbiota transplant

KW - Live biotherapeutic products

KW - Microbiome

KW - Recurrent C difficile

UR - https://www.scopus.com/pages/publications/105013132950

U2 - 10.1016/j.idc.2025.07.007

DO - 10.1016/j.idc.2025.07.007

M3 - Article

C2 - 40796472

AN - SCOPUS:105013132950

SN - 0891-5520

VL - 39

SP - 663

EP - 683

JO - Infectious disease clinics of North America

JF - Infectious disease clinics of North America

IS - 4

ER -

Microbiome Therapeutics for Clostridioides difficile Infection

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this